Tempus AI, Inc. (TEM) Debt to Assets Ratio: 0.36%
The debt to assets ratio for Tempus AI, Inc. (TEM) is 0.36% as of Friday, June 12, 2026.
TEM Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
0.36%
TEM Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO |
|---|---|---|
| Tempus AI, Inc. (TEM) | $8.65B | 0.36% |
| Charles River Laboratories International, Inc. (CRL) | $8.94B | 0.43% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.92B | 0.14% |
| Baxter International Inc. (BAX) | $10.58B | 0.50% |
| Hims & Hers Health, Inc. (HIMS) | $6.19B | 0.59% |
| Align Technology, Inc. (ALGN) | $12.27B | 0.02% |
| Solventum Corporation (SOLV) | $13.72B | 0.35% |
| Hologic, Inc. (HOLX) | $16.97B | 0.29% |
| 23andMe Holding Co. (ME) | $15.31M | 0.43% |
| Moderna, Inc. (MRNA) | $18.71B | 0.16% |
Leverage Ratios Comparison
Debt/Assets
0.4%
Debt/Equity
1.66
Current Ratio
3.13
Interest Coverage
-3.4x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Tempus AI, Inc. Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Tempus AI, Inc. Debt to Assets Ratio FAQ
- What is the debt to assets ratio for Tempus AI, Inc. (TEM)?
- The debt to assets ratio for TEM stock is 0.36%.
About Tempus AI, Inc.
Tempus AI, Inc. functions as a pioneering health technology enterprise. It specializes in delivering advanced diagnostic services, including cutting-edge genomic sequencing, PCR analysis, molecular genotyping, and various other anatomical and molecular pathology assessments. These vital services are provided to a diverse clientele, including medical practitioners, pharmaceutical companies, biotechnology innovators, scientific researchers, and other collaborating entities. The company offers "Insights," a licensed repository of de-identified clinical, molecular, and imaging data, complemented by a comprehensive suite of analytical and cloud-based computing services, primarily aimed at pharmaceutical and biotechnology firms. Additionally, its "Trials" program facilitates clinical trial matching services specifically for pharmaceutical companies. Tempus AI also manages several other platforms: "Next"; "Algos," a collection of algorithm-driven tests focused on oncology; "Hub," a versatile desktop and mobile application for ordering, managing, and receiving test results for patients; and "Lens," a dedicated portal enabling researchers and scientists to discover, access, and analyze the extensive Tempus dataset. Further demonstrating its commitment to innovation, Tempus AI has formed strategic alliances with AstraZeneca and Pathos AI, Inc. for the co-development of oncological therapeutic initiatives. Established in 2015, the company was initially known as Tempus Labs, Inc. before officially rebranding to Tempus AI, Inc. in January 2023. Its operations are based out of Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Eric Lefkofsky